[ Price : $8.95]
FDA posts 20 potential signals of serious risks/new safety information from the fourth quarter of 2023.[ Price : $8.95]
Rep. David Schweikert introduces legislation to require HHS to approve a fast-track designation for treatments for addictive subst...[ Price : $8.95]
FDA makes available a draft guidance entitled Data Integrity for In Vivo Bioavailability and Bioequivalence Studies.[ Price : $8.95]
Gritstone Bio reports mixed data from an ongoing Phase 2 portion of a Phase 2/3 study evaluating Granite, a personalized neoantige...[ Price : $8.95]
Eli Lilly says any revision of an FDA guidance on weight management drugs should incorporate a modern scientific characterization ...[ Price : $8.95]
A report by Spotlight on America suggests FDA is increasing scrutiny over CooperSurgical and its manufacturing facility in North T...[ Price : $8.95]
FDA posts a guidance entitled FDA Regional Implementation Guide for E2B(R3) Electronic Transmission of Individual Case Safety Repo...[ Price : $8.95]
Federal Register notice: FDA makes available a draft guidance entitled Draft Guidance on Oxymetazoline Hydrochloride.